Oxford Pharmascience scouts marketing partners for new pain meds

Oxford Pharmascience is hunting for a marketing partner for two new pain drugs. The U.K.-based pharma started contacting big drugmakers last fall, and has now hired consultants to pursue a deal on OXPzero Ibuprofen and OXPzero Naproxen. The new meds are reformulations of the two common pain relievers, tweaked to taste better and minimize digestive upset. Release

Suggested Articles

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.

The FDA wants to know what, exactly, is in a drug name—and whether it influences how the product is perceived. So it's launching a study to find out.

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.